Global Pharma Giants Concered About China’s New Anti-Monopoly Law
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Leading executives at multinational firms operating in China, including some pharmaceutical giants, are concerned that the country's new anti-monopoly law could be used to counter strong market positions or to forced licensing of innovative products to competitors
You may also be interested in...
China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
Merger watchers were keeping close tabs on whether one-year-old Anti-Monopoly Law would be used to block deal in China; divestments include an animal vaccine business.
China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
Merger watchers were keeping close tabs on whether one-year-old Anti-Monopoly Law would be used to block deal in China; divestments include an animal vaccine business.
China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
BEIJING - China's Ministry of Commerce has ordered Pfizer and Wyeth to divest themselves of certain business operations here in order to gain government approval for their $68-billion merger